CLINICAL CASE: USE OF CANAKINUMAB IN A PATIENT WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS RESISTANT TO IMMUNOSUPPRESSANTS AND GENETICALLY ENGINEERED BIOPHARMACEUTICALS

CLINICAL CASE: USE OF CANAKINUMAB IN A PATIENT WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS RESISTANT TO IMMUNOSUPPRESSANTS AND GENETICALLY ENGINEERED BIOPHARMACEUTICALS

The article presents a case of successful use of an interleukin-1 monoclonal antibody drug (canakinumab) for severe systemic juvenile idiopathic arthritis refractory to treatment with classic immunosuppressants and genetically engineered biopharmaceuticals with a different mode of action. Canakinuma...

Full description

Saved in:
Bibliographic Details
Main Authors: E. I. Alexeeva, R. V. Denisova, T. V. Sleptsova, T. M. Bzarova, K. B. Isaeva, E. V. Mitenko, E. G. Chistyakova, A. M. Chomakhidze, N. I. Taybulatov, A. N. Fetisova, O. L. Lomakina, S. I. Valieva
Format: Article
Language:Russian
Published: Union of pediatricians of Russia 2014-03-01
Series:Педиатрическая фармакология
Subjects:
systemic juvenile idiopathic arthritis
canakinumab
children
Online Access:https://www.pedpharma.ru/jour/article/view/127
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The article presents a case of successful use of an interleukin-1 monoclonal antibody drug (canakinumab) for severe systemic juvenile idiopathic arthritis refractory to treatment with classic immunosuppressants and genetically engineered biopharmaceuticals with a different mode of action. Canakinumab treatment shortly provided reduction in clinical and laboratory parameters of the disease activity, life quality improvement, development of an inactive disease stage and allowed reducing the prednisolone dose by 90% and avoiding intravenous and intraarticular administration of glucocorticoids.
ISSN:1727-5776
2500-3089

Similar Items